FDA approves Reblozyl treatment for anemia linked to myelogeny abnormal syndrome
-
Last Update: 2020-06-22
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Bristol Myers Squibb recently announced that the FDA has expanded the scope of reblozyl's indications to allow Reblozyl to treat anemia associated with low-risk myelogeny syndrome (MDS)The company acquired the development and sale rights of the red blood cell maturant Reblozyl (luspatercept-aamt), which received FDA approval in November 2019 to treat beta thalassemia that requires regular infusion of red blood cells (RBC) through the acquisition of CelgeneThe FDA's approval is based on the results of the Critical Phase III MEDALIST trial published on NEJM in January 2020The results showed that patients in the Reblozyl group reached the primary endpoint of the study within at least eight weeks compared to placebosReblozyl (luspatercept-aamt) is a soluble fusion protein that is combined by the fc domain of human IgG1 with the extrinsic domain of activator IIB receptor (ActRIIB) as a ligand trap that reduces the activation of smad2/3 signals by targeting specific ligands that regulate the late-stage RBC mature conversion growth factor (TGF)-beta superfamily
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
